Healome Therapeutics is a UK biotechnology company developing eye-drop matrix technology
for ocular surface disease. The platform is designed to improve retention, lubrication, protection,
healing and drug delivery on the ocular surface. Spun out of the University of Birmingham,
Healome combines expertise in biomaterials, regenerative medicine, ophthalmology and
translational science.
Healome Therapeutics: Venture Capital Funding History
Healome Therapeutics
Healome Therapeutics
- Life Sciences
- Birmingham, United Kingdom
- £2m
- healometx.com
- Update Information
More venture news
- 26 Oct 2026

adsilicoadsilico unlocks a £10m Series A round led by PXN Ventures for virtual testing of implantable medical devices
Series ALife Sciences - 26 Oct 2026

imphatecimphatec raises a £1.5m seed round led by SynBioVen to develop customisable-dose implants for chronic conditions
SeedLife Sciences - 15 Oct 2026

OMass TherapeuticsOMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences
